

Please address correspondence to:
![]() |
Canadian Cancer Trials Group
|
![]() |
(613) 533-6430 |
![]() |
(613) 533-2941 (613) 533-2411 |
CCTG Contact List (requires password to access) |
Protecting Cancer Patients from COVID-19In the race to find new ways to prevent and treat COVID-19, CCTG has launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients. More >> |
![]() CCTG Announces Initiation of IND.239CCTG has announced the commencement of a Phase II study of CFI-400945, an oral, first-in-class inhibitor of Polo-like Kinase 4 in combination with durvalumab, a PD-L1 checkpoint inhibitor, in patients with advanced or metastatic triple negative breast cancer. More >> |
Please address correspondence to:
![]() |
Canadian Cancer Trials Group
|
![]() |
(613) 533-6430 |
![]() |
(613) 533-2941 (613) 533-2411 |
CCTG Contact List (requires password to access) |